Revelation Biosciences (REVB) Long-Term Investments (2020 - 2021)
Revelation Biosciences (REVB) posted quarterly Long-Term Investments of $48.3 million for Q4 2021, down 34.29% year-over-year from $73.5 million in Q4 2020, and down 34.3% quarter-over-quarter from $73.5 million in Q3 2021.
Revelation Biosciences (REVB) Long-Term Investments (2020 - 2021) Analysis & Trends
Revelation Biosciences (REVB) has reported Long-Term Investments for 2 consecutive years, with $48.3 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Long-Term Investments fell 34.29% year-over-year to $48.3 million; the TTM figure through Dec 2021 stood at $48.3 million (down 34.29% YoY), while the FY2021 annual figure was $48.3 million, down 34.29% from the prior year.
- Long-Term Investments fell to $48.3 million in Q4 2021 per REVB's latest filing, from $73.5 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $73.5 million in Q3 2021 and bottomed at $48.3 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 48.30 Mn |
| Sep 30, 2021 | 73.52 Mn |
| Jun 30, 2021 | 73.51 Mn |
| Mar 31, 2021 | 73.51 Mn |
| Dec 31, 2020 | 73.51 Mn |